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Abstract
Objective—We tested the feasibility and efficacy of an electronic health record (EHR) strategy 
that automated the delivery of print medication information at the time of prescribing.
Methods—Patients (N = 141) receiving a new prescription at one internal medicine clinic were 
recruited into a 2-arm physician-randomized study. We leveraged an EHR platform to 
automatically deliver 1-page educational ‘MedSheets’ to patients after medical encounters. We 
also assessed if physicians counseled patients via patient self-report immediately following visits. 
Patients’ understanding was objectively measured via phone interview.
Results—122 patients completed the trial. Most intervention patients (70%) reported receiving 
MedSheets. Patients reported physicians frequently counseled on indication and directions for use, 
but less often for risks. In multivariable analysis, written information (OR 2.78, 95% CI 1.10–
7.04) and physician counseling (OR 2.95, 95% CI 1.26–6.91) were independently associated with 
patient understanding of risk information. Receiving both was most beneficial; 87% of those 
receiving counseling and MedSheets correctly recalled medication risks compared to 40% 
receiving neither.
Conclusion—An EHR can be a reliable means to deliver tangible, print medication education to 
patients, but cannot replace the salience of physician-patient communication.
Practice implications—Offering both written and spoken modalities produced a synergistic 
effect for informing patients.
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1. Introduction
In 2012, 2.3 billion prescriptions were ordered in ambulatory care and 67.2% of visits 
involved drug therapy [1]. Approximately 1.5 million preventable adverse drug events occur 
each year, with more than one-third taking place in outpatient settings at a cost approaching 
$1 billion per year [2]. Recent studies have repeatedly highlighted the alarming prevalence 
of patient misunderstanding and misuse of prescription medications [2-6]. Patients often 
lack sufficient information pertaining to medication indications, dosing instructions, side 
effects, and important risks and warnings. Limited understanding of these aspects of 
prescription medications can lead to improper use, underreporting of adverse drug events 
(ADEs) and non-adherence, ultimately resulting in poor health outcomes [2,3,7,8]. This is a 
concern for both healthcare quality and patient safety, as these individuals may not optimize 
the benefits of drug therapy, and/or have a higher risk of adverse drug events.
1.1. Insufficient counseling could be a potential reason for patients being inadequately 
informed about prescribed medicines
Prior studies indicate patient-provider spoken communication about medications is 
inadequate; both physicians and pharmacists frequently fail to discuss the safe use of 
prescribed medications with patients [9-14]. When counseling does occur, providers may 
overestimate the clarity of instructions they give to patients [15]. Some physicians are 
admittedly reluctant to discuss side effects, as they may be worried this will result in non-
adherence, or they may assume pharmacists will convey this information [16,17]. However, 
patients indicate they would like to know about the associated side effects of their new 
medications and are frequently not provided with this information from their physician [18]. 
Low quality or non-existent communication about medications from prescribers has been 
linked to patient misunderstanding, lack of awareness of risks, and/or non-adherence 
[19-22]. Ineffective verbal communication by both prescribers and pharmacists can also 
influence whether a prescription will be initiated or remain unfilled or unused [23-25].
In addition to suboptimal counseling, evidence also suggests that the tangible, written 
materials distributed to patients at the pharmacy are neither understandable nor actionable 
[26-30]. Whether it be a perceived lack of importance or their complex nature, these 
medication educational materials more often are neglected by patients, further contributing 
to the problems of misunderstanding and medication errors.
Subsequently, we developed an electronic health record (EHR) strategy to ensure patients 
would receive understandable, actionable information at the point of prescribing to support 
safe medication use. Our objective was to test the feasibility of this strategy, examine 
naturally occurring provider communication, and test the impact of each on the 
understanding and proper use of newly prescribed prescription medications.
2. Methods
2.1. Participants and procedure
Study participants were recruited between September 2009 and February 2012 from the 
Northwestern Medical Faculty Foundation (NMFF) general internal medicine (GIM) clinic 
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in Chicago, IL. Participants were deemed eligible if they were 1) English-speaking, 2) 
without cognitive, vision, or hearing impairment, 3) without any significant, acute health 
condition, 4) between the ages of 18–80, and 5) received one or more new or changed 
prescriptions for the 50 study medications on the day of recruitment. Patients with 
prescription refills only were not eligible. Clerical and medical staff were made aware of the 
project, flyers were distributed in patient folders and at checkout, and trained study research 
assistants (RAs) were in the clinic during high volume periods to invite participants deemed 
eligible for the study. Immediately after a scheduled patient visit, patients were approached 
at checkout by an RA to assess interest, confirm eligibility, and obtain consent. Once 
consented to the study, patients completed a brief baseline battery including an assessment 
of provider communication. Upon completion of the in-person interview, participants were 
given $10 in cash. An RA then administered a follow-up phone call two weeks later to 
determine if medications were filled, and if so, to assess patient understanding on proper use 
of the new medication(s). The Northwestern University Institutional Review Board approved 
the study.
2.2. Intervention
2.2.1. Creation of ‘MedSheets’—We consulted the literature, patients, and clinicians 
(physicians, nurses, and pharmacists) to gain perspective on a prototype for providing clear, 
understandable, and actionable information to patients receiving a new medication. Topics 
were logically sequenced from a patient’s perspective: drug name, purpose, benefit, length 
of treatment, instructions, safe use, important side effects and warnings, when to call your 
doctor, discussion points, relevant follow-up instructions, and where to get more 
information. The prototype was vetted and approved by the study team, including clinicians, 
health literacy and health communication experts, and two patient representatives. The top 
500 prescribed medicines for NMFF GIM were reviewed, and ‘MedSheets’ were developed 
for 305 medications covering the previously approved topics. Further revisions to specific 
content and wording were conducted by the team. An outside panel of 3 pharmacists and 1 
physician did an ultimate review to confirm accuracy. Lexile analyses were performed on all 
final MedSheets, confirming that each met a <8th grade readability standard. Two sample 
MedSheets are shown in Fig. 1.
2.2.2. Delivery of ‘MedSheets’—Code was written within Epic’s EHR platform (Epic 
Systems Corporation; Verona, Wisconsin) to link pdf versions of the MedSheets to new or 
changed medication orders. The intervention was designed to print one of 50 MedSheets 
when the particular medication was ordered. Due to limited programming resources, only 
the 50 most frequently prescribed medications in NMFF’s GIM clinic were included. The 
intervention was beta tested for two weeks prior to enrolling participants to monitor the 
reliability and delivery. Minor modifications were made at the clinic’s request for the 
MedSheets to print at the check-out desk rather than at nurse’s stations. This was done as to 
not disrupt clinicians’ workflow and to increase the likelihood the patients would actually 
receive the MedSheets with their after visit summaries.
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2.3. Randomization
A simple 1:1 randomization scheme was not possible, as the EHR function to generate the 
‘MedSheets’ could not be applied at the individual patient level. Rather, Epic did allow us to 
turn the intervention components on or off by prescriber. Therefore, attending physicians 
were randomized to either the intervention or usual care arm by first stratifying them by 
clinical effort (full time, half time), then randomly assigning physicians within each 
stratification to study arm. Residents were not able to be randomized due to frequent 
turnover and they were not directly linked with their assigned attending within the EHR, so 
eligible patients who were prescribed medications by a resident were all assigned to the 
control group.
2.4. Measures
2.4.1. Patient characteristics—Interview questions included self-report of 
sociodemographic information (age, gender, race/ethnicity, education, income, work status, 
marital status) and total number of chronic conditions including diabetes, chronic obstructive 
pulmonary disease, coronary vascular disease, coronary heart failure, asthma, hypertension, 
hypercholesterolemia, stroke, arthritis, cancer, depression (0–11). Participants were asked 
how many prescription and over-the-counter medications they were currently taking. Patient 
literacy was also assessed using the Rapid Estimate of Adult Literacy in Medicine 
(REALM), a word-recognition test where patients are asked to read aloud as many words as 
they can from a list of 66 health related terms [31]. Scores are based on the total number of 
words pronounced correctly and interpreted as low (0–44), marginal (45–60), or adequate 
(61–66) literacy.
2.4.2. Medication characteristics—Medications were categorized based on typical 
prescribing patterns. Medications typically prescribed chronically for regularly scheduled 
use (e.g., cardiovascular, antidiabetic, and antidepressant medications) were labeled as 
‘chronic.’ Those which may be typically used for a time limited period (e.g. anti-infective 
agents, corticosteroids), or used as needed for symptoms (e.g., analgesics), were classified as 
non-chronic.
2.4.3. Provider communication—At the baseline interview, participants were asked 
whether their doctor talked to them (yes/no) about the indication, benefits, possible side 
effects, risks and warnings, how long they should take the medication, and exactly how to 
take the medication for each new medication prescribed. Specific questions are listed in Fig. 
2.
2.4.4. Prescription understanding and proper use—At follow-up, patients were 
asked if they filled their medication and if so, questions were asked to assess understanding 
and proper use of their new prescriptions. Questions parallel to the provider communication 
items were asked per new medication. This included patients being asked what the medicine 
was for, to name any risks and benefits of the drug, how long they should take the drug, and 
to describe how they take the medicine, similar to prior. Participants were allowed to refer to 
their MedSheets during this assessment. Specific questions that were asked are listed in Fig. 
2. Answers to each question were coded (correct or incorrect) by four RAs based on 
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previously defined criteria, and discrepancies were reconciled by a Pharm D. In reviewing 
participant responses to questions asking them to name any possible side effects, risks, or 
warnings, it was clear many were unable to distinguish the difference. Therefore, this 
component was coded correct if the participant was able to name at least one side effect, 
risk, or warning. Participants were asked to indicate the correct number of pills they take at a 
time, the correct number of times a day they take the medicine, and the total number of pills 
they take each day. Each was coded as correct/incorrect according to their bottle’s 
instructions and considered to have demonstrated proper use of their medications if all three 
were correct. This has served as a common outcome in previous studies [6,32-36]. The 
instructions prescribed for each new medication were obtained from the patients’ medical 
records, but also confirmed with patients on the phone call to ensure similar instructions 
were printed on the bottle.
2.4.5. Patient receipt and preferences of intervention—At follow-up, patients in the 
intervention arm were asked if they received any written information about their new 
medication with their after-visit summary. Those who reported receiving the sheets, were 
asked if they looked at them since receiving and whether they looked at any other sources of 
information about their medications. Those who reported looking at the MedSheets were 
asked if they contained too much information, too little, or about the right amount. They 
were also asked to rate the information on the sheets on a scale from 1 to 10 with 1 being not 
at all clear and 10 being very clear. Helpfulness was similarly assessed.
2.5. Analysis
Patient characteristics including age, sex, race/ethnicity, education, income, literacy level, 
number of comorbid conditions, and total number of prescription and OTC medications 
taken were summarized. These characteristics along with whether their physician counseled 
them on either of their new prescriptions (yes or no) were compared by study arm using t-
tests and Pearson Chi-Square tests, as appropriate, to ensure adequate balance in the two 
arms.
Generalized linear models with a binomial distribution and logit link function were used to 
model patient understanding and proper use of newly prescribed medications (correct, 
incorrect). A generalized estimating equation (GEE) approach was used with medication as 
the unit of analyses, adjusting model coefficients and standard errors for within-patient 
correlation. Separate models were run for each aspect of understanding and proper use: 
indication, benefits, risks and warnings, duration of use, and specifically how they take their 
medication over the course of a day. Unadjusted GEE models were first run to examine 
associations between potential patient and medication level covariates described above and 
patient understanding. For each multivariable model, the primary independent variables of 
interest were arm (usual care, intervention) and whether physician counseling occurred for 
each particular outcome (yes, no). Other covariates included any variables found to differ by 
arm or patient understanding in preliminary analyses (p <0.05). Then, to examine the 
isolated and combined effects of the written materials (MedSheets) and physician counseling 
on each outcome, adjusted probabilities were examined in each of the following groups: 
intervention only, counseling only, both, or neither. This study was analyzed as intent-to-
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treat despite some of the patients not receiving the intervention. Statistical analyses were 
performed using STATA 13.1 (College Station, TX).
3. Results
3.1. Study population
Of the 1097 patients RAs approached, 68 declined and 865 were ineligible, leaving 164 
consented patients. The majority of ineligible patients did not receive a new prescription, 
received a refill, or received a new medication other than one of the 50 study medications. 
There were 141 completed baseline interviews and 127 (90%) of those patients also 
completed the follow-up phone call. Patients were prescribed 137 new medications and the 
majority (97%) were filled. The 122 patients that filled at least one medication were 
included in this analysis.
3.2. Participant characteristics
Patients had a mean (SD) age of 53 (15) years, were 76% female, 38% African American, 
44% White, highly educated with over half having a college education, and had an average 
of 2 chronic conditions. Despite randomization, intervention participants were more likely to 
be White, have a college degree, higher literacy levels and income, and fewer chronic 
conditions (see Table 1). Physician counseling did not differ by any of these characteristics.
3.3. Fidelity of the intervention
Intervention participants reported receiving information for their medicines with their after-
visit summary 70% of the time. Clinic staff indicated some MedSheets were not received 
due to printer malfunctioning, unrelated to the programming of the intervention. Of those 
who reported receiving the sheets (n = 44), 75% reviewed them at some point since their 
visit. Fourteen (32%) reported looking at other information about their medications 
including information from the pharmacy (8/14), online (5/14), and television (1/14). Of 
those who reported looking at the sheets (n = 33), 91% found the amount of information to 
be about adequate (3% too much, 6% too little). The majority (79%) rated the MedSheets as 
a 9 or 10 on a scale from 0 to 10 for being clear, and 73% rated them a 9 or 10 for being 
helpful.
3.4. Provider communication
Overall, patient-reported communication by providers about new prescriptions about 
indication, benefits, and directions for use was very high (98%, 90%, and 82%, respectively) 
and counseling about duration of use was moderate (68%). However, only 47% of patients 
reported that the providers counseled on the side effects, risks or warnings of newly 
prescribed medications. Counseling on duration of use was less likely to occur for chronic 
medications (57%, p = 0.01) compared to non-chronic medications (78%).
3.5. Patient understanding and proper use
Patient understanding of indication and benefits were also high (87% and 84%, 
respectively). The majority of patients were able to identify at least 1 side effect, risk, or 
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warning (79%) with those in the intervention being more likely to do so than those in the 
usual care group (87% vs 71%, p = 0.03). Patients in the intervention group were also more 
likely to know the duration of their new prescription than those in usual care. There were no 
differences by arm in any of the other components (see Table 2).
Multivariable models adjusting for age, race, income, literacy level, total number of chronic 
conditions, and medication type (chronic, non-chronic) are shown in Table 3. Doctors 
discussing duration of use was associated with better understanding of this component (OR 
8.04, 95% CI 2.35–27.48, p = 0.001). Both being assigned to the intervention arm (OR 2.78, 
95% CI 1.10–7.04, p = 0.03) and receiving communication from their doctor (OR 2.95, 95% 
CI 1.26–6.91, p = 0.01) were independently associated with recall. When looking at adjusted 
probabilities of understanding each component, those that received information about side 
effects or risks either from the MedSheets only (65%) or from the physician only (66%) 
were similar in reporting at least one while 87% of patients were able if they received both. 
Very few knew this information if it was not communicated at all (40%). Similar results 
were found regarding duration of use: 87% physician only, 74% MedSheet only, 97% both, 
and 53% neither.
4. Discussion and conclusion
4.1. Discussion
Our study, conducted at one general internal medicine clinic, demonstrated moderate 
feasibility and reliability of leveraging an electronic health record to deliver low literate, 
actionable information to patients about the safe use of newly prescribed medications at the 
point of prescribing. Importantly, this function did not require any modifications to clinician 
workflow as MedSheets were automatically generated with after-visit summaries once a 
medication was ordered. The only change to clinic processes was asking clerical staff to 
hand the Medsheet to patients along with their after visit summary, which patients reported 
to occur 70% of the time. Findings also suggest that giving medication information at the 
point of prescribing does hold some significant benefits, particularly in improving patient 
understanding of side effects, risks, and warnings associated with medicines. Yet perhaps 
most telling was the greater knowledge in those who received this information when 
counseled in parallel by their physician during the medical encounter on the safe use of their 
medication.
Patients reported that physicians frequently communicated indication, benefits, and 
directions for use, but infrequently counseled about risks and warnings when prescribing a 
medication for the first time. Prior studies found similar, if not lower, rates of physicians 
counseling patients on side effects and risks compared to other medication attributes in both 
audiotaped encounters [10] and when counseling was self-reported by patients [11,37]. 
Evidence has reported upon clinicians’ reservations to discuss associated medication side 
effects as it may potentially negatively impact adherence [16,38]. In a study looking at risk 
information provided when prescribing NSAIDS by Schmitt et. al., patients reported 
counseling occurred less than one third of the time and was linked to limited understanding 
of the risks [19].
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In our study, overall rates of patient understanding of both indications and benefits were 
relatively high, so it is not surprising that neither our intervention nor patient report of 
physician counseling about these components improved understanding. Yet both strategies, 
alone and in combination, did manage to remedy noted knowledge deficits in recall of side 
effects, risks and warnings as well as knowledge about duration of use. However, we were 
unable to examine whether or not improved knowledge translated to any influence—good or 
bad—on a patient’s adherence and/or clinical outcomes.
The intervention did ensure the majority of patients were given clear, understandable written 
information as they left the clinic. Our strategy was intentionally designed not to change 
what doctors discussed with patients during their encounters; changing physician behavior is 
known to be challenging, especially in the U. S. among primary care physicians given the 
pressures of managed care, workflow, and the number of patients to be seen daily. We sought 
to ensure that patients, regardless of the extent and quality of counseling received at the time 
of a medication order, received tangible written information without affecting physicians’ 
routine. Patients have indicated preferring to receive this information about their medications 
from their doctor rather than at the point of dispensing a medication (pharmacy) [17]. This is 
not surprising, as information received at the pharmacy is written at a level that is difficult 
for most patients to understand [26-28,30]. In addition, Schmitt et al. found written 
information received from the pharmacy did not benefit patient knowledge of important risk 
information [19]. Yet our discovery of a synergistic effect between receipt of written and 
spoken risk communication, compared to either alone, supports evidence that we should not 
rely on the passive delivery of the MedSheets alone to adequately inform patients on safe 
medication use and expectations to have when initiating a new prescription [38].
To that end, the hard work of seeking an effective means to prompt and support physician-
patient communication at the time of a new prescription should be a logical next step. The 
MedSheets described in this study can be used as a ‘plain language script’ for physicians to 
standardize what a doctor might convey to a patient with a new prescription during the 
encounter. An electronic view of the MedSheet can be easily retrieved via a prompt for 
medications as the physician enters the order. Ideally, such a system would respond to our 
study findings by creating a unified system of written and spoken communication as 
recommended by experts in the field [38]. Our team has already taken action and is 
designing a means to leverage the EHR to prompt and track physician counseling for higher 
risk medications. In addition, electronic versions of the sheets could easily be delivered to 
patients via additional modalities (e.g. patient portal, website).
Our study was done in a small sample in one general internal medicine clinic in one EHR 
platform, therefore we cannot generalize our findings to broader populations. We analyzed 
our study as an intent-to-treat analysis when approximately 30% of participants reported not 
receiving the intervention. However, we expect results would be stronger if everyone in that 
study arm received the intervention. The quality and extent of counseling was also not 
assessed. Whether or not provider counseling occurred was self-reported by the patient soon 
after their medical encounter. It is possible there was error due to recall of the patient and 
counseling did occur. However, Tarn 2006’s results assessing the same aspects of provider 
counseling from audiotaped sessions were similar, if not lower [10]. Even if counseling did 
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occur and patients were unable to recall this information immediately after their 
appointment, this provides further justification for the need to also provide tangible print 
information.
Due to the diffuse nature of the intervention being programmed in the EHR, randomization 
needed to occur at the physician level, rather than at the patient level. This makes it more 
difficult to ensure patient characteristics are completely balanced by study arm, as evidenced 
in Table 1. Our study arms differed significantly by age, race, literacy level, income, and 
number of comorbid conditions. These factors were adjusted for in analyses, but it raises the 
question as to whether groups differed by other important unmeasured covariates. Finally, 
assigning all residents to the control arm could have introduced bias in our estimates.
4.2. Conclusion
This EHR-based intervention was promising in terms of feasibility of delivering patient 
education through the EHR without affecting clinician workflow, as well as efficacious in 
addressing certain deficits in patient understanding of their newly prescribed medications. 
This is one example of an efficient and sustainable means to educate patients on newly 
prescribed medications. We also found patient self-report of physician counseling to be low, 
particularly for side effect, risk, and warning information; however, when counseling did 
occur, patients demonstrated better understanding. The combined effect of the written and 
spoken communication conceivably is a rational finding, and herein we offer a model for 
assuring the former, while stressing the need to promote the latter.
4.3. Practice implications
The majority of primary care practices in the U.S. now house an EHR system, yet may 
continue to struggle to harness its potential for patient education and engagement functions. 
The use of MedSheets in our intervention were a simple upload that provided assurances of 
informing patients on new medication, while having little to no impact on workflow. More 
importantly, our findings underscore the need to further engage physicians and support their 
capability to have meaningful discussions with patients when prescribing medications. This 
may necessitate the use of decision aids, strategies like EMC2, medical education, or quality 
improvement efforts to hardwire opportunities to adequately counsel patients.
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Fig. 1. 
Examples of chronic and non-chronic MedSheets.
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Fig. 2. 
Physician communication and patient understanding measures per new medication.
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Table 1
Participant characteristics by study arm.
Total Control Intervention P Value
(N = 141) (n = 74) (n = 67)
Age, M (SD) 52.8 (14.7) 54.1 (15.1) 51.3 (14.3) 0.27
Female, % 75.9 74.3 77.6 0.65
Race/Ethnicity, %
 Black 37.6 47.3 26.9 0.01
 White 44.0 32.4 56.7
 Other 18.4 20.3 16.4
Education, %
≤ High School 17.7 24.3 10.5 0.03
Some college 22.7 25.7 19.4
≥ College Graduate 59.6 50.0 70.1
Literacy Level, %
Low 5.7 9.5 1.5 <0.001
Marginal 15.7 25.7 4.6
Adequate 78.6 64.8 93.9
Annual Income, %
< $15,000 21.2 29.6 12.1 0.004
$15,000-$49,999 33.6 38.0 28.8
≥ $50,000 45.3 32.4 59.1
# Comorbid conditions, M (SD) 1.9 (1.6) 2.4 (1.7) 1.4 (1.3) <0.001
# Rx medications, M (SD) 4.4 (4.7) 5.1 (4.5) 3.8 (4.8) 0.10
# OTC medications, M (SD) 1.8 (1.4) 2.0 (1.5) 1.7 (1.4) 0.06
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